Previous 10 | Next 10 |
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning PR Newswire PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. ...
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients PR Newswire PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patien...
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today ...
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease PR Newswire CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a...
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting PR Newswire Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinic...
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 PR Newswire Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. ...
2024-04-11 06:08:22 ET More on NeuroSense Therapeutics Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information for NeuroSense Therapeutics Read the full article on Seeking Alp...
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics PR Newswire NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in ...
2024-04-08 01:22:51 ET More on NeuroSense Therapeutics Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information for NeuroSense Therapeutics Read the full article on Seeking Alp...
2024-04-05 14:55:10 ET More on mid-day movers & stock 22nd Century Group, Inc. (XXII) Q4 2023 Earnings Call Transcript Grindrod Shipping: Favorable Outlook, M&A Completion, And Very Cheap Grindrod Shipping: When A Young Fleet And Healthy Financials Are Not En...
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...